Cisplatin-based combination chemotherapy for disseminated germ cell tumors

Long-term follow-up

B. J. Roth, A. Greist, P. S. Kubilis, S. D. Williams, Lawrence Einhorn

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

A retrospective analysis of the initial 229 cases of disseminated germ cell tumors treated at Indiana University with cisplatin, vinblastine, and bleomycin (PVB), with or without doxorubicin revealed 146 pateints who are alive and disease-free with a minimum follow-up of 6 years and a median follow-up of 8.5 years. At 12 years, the estimated probability of survival is 65.0%, and the estimated probability of relapse-free survival for complete responders is 83.5%. Long-term complications, such as clinically significant organ toxicity or therapy-related second malignancies, have not been observed. The functional status of survivors is maintained, with 95% returning to their pretherapy status, of which 88% are fully employed. Of patients receiving chemotherapy without abdominal surgery, 35% have fathered healthy children posttherapy. Achievement of complete remision (CR) in disseminated germ cell tumors with cisplatin-based combination chemotherapy translates to long-term disease-free survival and cure for the majority of patients, with preservation of functional status.

Original languageEnglish
Pages (from-to)1239-1247
Number of pages9
JournalJournal of Clinical Oncology
Volume6
Issue number8
StatePublished - 1988

Fingerprint

Germ Cell and Embryonal Neoplasms
Combination Drug Therapy
Cisplatin
Survival
Second Primary Neoplasms
Vinblastine
Bleomycin
Doxorubicin
Disease-Free Survival
Survivors
Recurrence
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cisplatin-based combination chemotherapy for disseminated germ cell tumors : Long-term follow-up. / Roth, B. J.; Greist, A.; Kubilis, P. S.; Williams, S. D.; Einhorn, Lawrence.

In: Journal of Clinical Oncology, Vol. 6, No. 8, 1988, p. 1239-1247.

Research output: Contribution to journalArticle

Roth, B. J. ; Greist, A. ; Kubilis, P. S. ; Williams, S. D. ; Einhorn, Lawrence. / Cisplatin-based combination chemotherapy for disseminated germ cell tumors : Long-term follow-up. In: Journal of Clinical Oncology. 1988 ; Vol. 6, No. 8. pp. 1239-1247.
@article{5d1d4f0b8e204114923878ffc296fca6,
title = "Cisplatin-based combination chemotherapy for disseminated germ cell tumors: Long-term follow-up",
abstract = "A retrospective analysis of the initial 229 cases of disseminated germ cell tumors treated at Indiana University with cisplatin, vinblastine, and bleomycin (PVB), with or without doxorubicin revealed 146 pateints who are alive and disease-free with a minimum follow-up of 6 years and a median follow-up of 8.5 years. At 12 years, the estimated probability of survival is 65.0{\%}, and the estimated probability of relapse-free survival for complete responders is 83.5{\%}. Long-term complications, such as clinically significant organ toxicity or therapy-related second malignancies, have not been observed. The functional status of survivors is maintained, with 95{\%} returning to their pretherapy status, of which 88{\%} are fully employed. Of patients receiving chemotherapy without abdominal surgery, 35{\%} have fathered healthy children posttherapy. Achievement of complete remision (CR) in disseminated germ cell tumors with cisplatin-based combination chemotherapy translates to long-term disease-free survival and cure for the majority of patients, with preservation of functional status.",
author = "Roth, {B. J.} and A. Greist and Kubilis, {P. S.} and Williams, {S. D.} and Lawrence Einhorn",
year = "1988",
language = "English",
volume = "6",
pages = "1239--1247",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Cisplatin-based combination chemotherapy for disseminated germ cell tumors

T2 - Long-term follow-up

AU - Roth, B. J.

AU - Greist, A.

AU - Kubilis, P. S.

AU - Williams, S. D.

AU - Einhorn, Lawrence

PY - 1988

Y1 - 1988

N2 - A retrospective analysis of the initial 229 cases of disseminated germ cell tumors treated at Indiana University with cisplatin, vinblastine, and bleomycin (PVB), with or without doxorubicin revealed 146 pateints who are alive and disease-free with a minimum follow-up of 6 years and a median follow-up of 8.5 years. At 12 years, the estimated probability of survival is 65.0%, and the estimated probability of relapse-free survival for complete responders is 83.5%. Long-term complications, such as clinically significant organ toxicity or therapy-related second malignancies, have not been observed. The functional status of survivors is maintained, with 95% returning to their pretherapy status, of which 88% are fully employed. Of patients receiving chemotherapy without abdominal surgery, 35% have fathered healthy children posttherapy. Achievement of complete remision (CR) in disseminated germ cell tumors with cisplatin-based combination chemotherapy translates to long-term disease-free survival and cure for the majority of patients, with preservation of functional status.

AB - A retrospective analysis of the initial 229 cases of disseminated germ cell tumors treated at Indiana University with cisplatin, vinblastine, and bleomycin (PVB), with or without doxorubicin revealed 146 pateints who are alive and disease-free with a minimum follow-up of 6 years and a median follow-up of 8.5 years. At 12 years, the estimated probability of survival is 65.0%, and the estimated probability of relapse-free survival for complete responders is 83.5%. Long-term complications, such as clinically significant organ toxicity or therapy-related second malignancies, have not been observed. The functional status of survivors is maintained, with 95% returning to their pretherapy status, of which 88% are fully employed. Of patients receiving chemotherapy without abdominal surgery, 35% have fathered healthy children posttherapy. Achievement of complete remision (CR) in disseminated germ cell tumors with cisplatin-based combination chemotherapy translates to long-term disease-free survival and cure for the majority of patients, with preservation of functional status.

UR - http://www.scopus.com/inward/record.url?scp=0023748580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023748580&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 1239

EP - 1247

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -